000 00705nam a2200109Ia 4500
008 230718s9999 xx 000 0 und d
100 _aMiguel Salavert et al
245 0 _aCost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spainq
650 _aComputer science, information & general works
856 _uhttps://new.zodml.org/sites/default/files/2023-07/cost-effectiveness_analysis_of_bezlotoxumab_added_to_standard_of_care_versus_standard_of_care_alone_for_the_prevention_of_recurrent_clostridium_difficile_infection_in_high-risk_patients_in_spain.pdf
942 _cEBK
999 _c20373
_d20373